Amyloid Imaging Surrogate Marker for Anti-Amyloid Therapy Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for amyloidosis, such as Alzheimer's Disease, lack effective methods to quantify amyloid load before treatment and assess treatment efficacy, hindering the development of anti-amyloid drugs.
Innovation Solution
A method involving amyloid imaging as a surrogate marker, using a compound with a specific formula to image patients before and after treatment with anti-amyloid agents, allowing for comparison of amyloid deposition levels to evaluate therapy efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If brain biopsy is used to determine the presence of AD, then diagnostic accuracy is improved, but patient safety deteriorates due to dangerous invasive procedure
Solution Approach 1:
The patent introduces amyloid imaging as an intermediary diagnostic tool that mediates between the need for accurate AD detection and the avoidance of dangerous brain biopsies. The imaging technique provides a non-invasive surrogate measurement that correlates with amyloid burden, enabling safe diagnosis without direct brain tissue sampling.
Solution Approach 2:
The patent replaces the mechanical invasive procedure of brain biopsy with a non-invasive imaging-based detection system. This substitution eliminates the physical trauma and safety risks associated with brain surgery while maintaining the ability to quantify amyloid load through imaging signals.
2Device complexity
If anti-amyloid therapies are developed without imaging markers, then drug development complexity is reduced, but treatment efficacy assessment capability deteriorates
Solution Approach 1:
The patent implements feedback mechanisms by using amyloid imaging to measure treatment response in real-time. The imaging data provides feedback on whether anti-amyloid therapies are effectively reducing amyloid burden, enabling researchers to assess efficacy and adjust treatment protocols based on quantitative imaging results.
Solution Approach 2:
The patent replaces subjective clinical assessment methods with objective imaging-based measurement systems. This substitution enables precise, quantifiable monitoring of therapy efficacy through imaging markers, providing reliable data for drug development decisions without complex mechanical measurement apparatus.
3Measurement precision
If amyloid imaging is performed frequently to monitor treatment response, then treatment monitoring accuracy is improved, but time and resource consumption increases
Solution Approach 1:
The patent applies preliminary action by establishing baseline amyloid imaging measurements before treatment initiation. This baseline provides reference data that enables more efficient monitoring during treatment, as changes from the baseline can be detected more quickly and accurately, reducing the frequency of imaging needed for comprehensive assessment.
Solution Approach 2:
The patent utilizes parameter changes in imaging signal intensity to track amyloid burden over time. By monitoring changes in imaging parameters rather than requiring repeated comprehensive scans, the system achieves accurate treatment monitoring with reduced time and resource investment, optimizing the balance between monitoring accuracy and efficiency.
Data Source
AI summary
The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.